AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03328052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MYnd Analytics PEER Online directed antidepressant therapy
Description: PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm.
Study NCT03328052 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional antidepressant therapy
Description: Anti-depressant therapy chosen based on physician best judgement.
Study NCT02700685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Description: Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
Study NCT02700685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Standard pharmaceutical treatment for ADHD, slow release.
Study NCT02700685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (identical capsules containing excipients only)
Study NCT03923608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal muscle strength Test
Description: 1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
Study NCT03923608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaustion test
Description: Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
Study NCT04627883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inspiratory-to-expiratory (I : E) ratio of 1:2
Description: After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
Study NCT04627883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inspiratory-to-expiratory (I : E) ratio of 2:1
Description: After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
Study NCT01026415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg IV every 21 days
Study NCT01026415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600 mg/day PO
Study NCT01026415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 1 mg IV
Study NCT01026415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 400 mg/day PO
Study NCT01026415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg IV every 21 days
Study NCT01806415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenobam
Description: Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
Study NCT01806415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo or lactose 150 mg
Study NCT03905382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative
Description: Focus group and 1:1 telephone interviews
Study NCT01581853 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/ritonavir 800 mg / 200mg
Description: Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
Study NCT02186938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac
Study NCT03432533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: romosozumab HCP administration with PFS
Description: 210 mg romosozumab SC QM by HCP administration with 2 PFS
Study NCT03432533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: romosozumab self-administration with AI/Pen
Description: 210 mg romosozumab SC QM by self-administration with 2 AI/Pens
Study NCT04645186 — intervention group
Intervention type: DEVICE
Intervention: bone graft substitute
Description: Filling bone defects in current clinical practice
Study NCT02362633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
Study NCT02362633 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
Study NCT02300311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonivamide + nicoboxil (Finalgon cream)
Description: 2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
Study NCT02300311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo matching nonivamide + nicoboxil (Finalgon cream)
Description: 2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
Study NCT01944943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
Study NCT00816582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline
Description: A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
Study NCT00816582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: 18F-FES PET/CT - Baseline
Description: A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
Study NCT00816582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up
Description: A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
Study NCT01653743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSJ-0011
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
Study NCT01653743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urinary hCG (u-hCG)
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
Study NCT01653743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alpha
Description: Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
Study NCT01653743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alpha
Description: Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
Study NCT03748771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApneaLink Air
Description: The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP.
Study NCT03246672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintenance intervention
Description: Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
Study NCT00209729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
Study NCT00209729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: Day 1-14, P.O. everyday
Study NCT03618303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI scan
Description: Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
Study NCT02113111 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fasting
Description: Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
Study NCT03605875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-App
Description: Cambian IT Health solutions from Surrey BC developed the infrastructure
Study NCT03605875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper
Description: Contains similar questions to the Web-App tool
Study NCT01631708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocytapheresis
Description: To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to \~100 ug/L in accordance with current guidelines.
Study NCT01631708 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Plasmapheresis
Description: An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
Study NCT01438437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAI
Description: Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
Study NCT01438437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
Study NCT04582045 — intervention group
Intervention type: DEVICE
Intervention: silver impregnated dressing
Description: comparison of Mepilex versus our standard techniques
Study NCT02171702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT03508271 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT02744469 — intervention group
Intervention type: OTHER
Intervention: No intervention (observational study)
Study NCT00821236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Laser
Description: WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
Study NCT00821236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO/VISX CustomVue™
Description: Excimer Laser
Study NCT00821236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LADARVision 4000 excimer laser
Description: Excimer Laser
Study NCT04007809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
Study NCT03297541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-health approach
Description: Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981). Anthropometric and demographic data collected on children in the dyad only.
Study NCT01132261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brain preservation' diet
Description: dietetic evaluation and advice in small group for health diet
Study NCT03647722 — intervention group
Intervention type: OTHER
Intervention: Assessment of leukocyte function.
Description: The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
Study NCT04391413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of OCT to guide the angioplasty procedure
Description: OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
Study NCT04992442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Oral Tablet
Description: TAK-935 tablet
Study NCT04992442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-935 IV Infusion
Description: \[14C\]TAK-935 IV infusion
Study NCT04992442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-935 Oral Solution
Description: \[14C\]TAK-935 oral solution
Study NCT04858620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xlear Nasal Spray
Description: Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours
Study NCT04858620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline nasal spray, 2 puffs per nostrils, every 6 hours
Study NCT00764972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Vinorelbine
Description: vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.
Study NCT01856491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RELIANCE 4-FRONT™ Passive Fixation lead implantation
Description: Implantation of transvenous defibrillation lead with passive fixation mechanism.
Study NCT00222729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 day 1 q 21 days
Study NCT03111069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery
Description: Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor.
Study NCT03111069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation.
Study NCT03111069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-Operative Radiation
Description: Standard dose brachytherapy delivered to the residual pelvic tumor sites.
Study NCT01231854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
Study NCT01231854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alitretinoin
Description: In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
Study NCT03300531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection
Description: Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
Study NCT03300531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet-rich-plasma (PRP) injection
Description: Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
Study NCT03300531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Compound betamethasone injection
Description: Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
Study NCT03436810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
Study NCT03436810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
Study NCT03436810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Task-Oriented Circuit Class Training
Description: Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.